Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06995898 · ClinicalTrials.gov registry record · NA
The Vanguard Study: Testing a New Way to Screen for Cancer
A NA study of Malignant Solid Neoplasm and Breast Carcinoma, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- NA
- Development phase
- 24,000
- Enrollment target
- 20
- Study locations
NCT06995898: Recruiting NA study of Malignant Solid Neoplasm and Breast Carcinoma, sponsored by National Cancer Institute (NCI).
NCT06995898 is a NA study of Malignant Solid Neoplasm and Breast Carcinoma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 24,000 participants, above the 1,004-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (2290% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06995898, a NA study of Malignant Solid Neoplasm and Breast Carcinoma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- NA
- Development phase
- 24,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).
Primary Outcome
The number of participants enrolled into the study compared to trial goals.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Electronic Health Record Review
- DEVICE Device Usage
- PROCEDURE Multi-Cancer Detection Test
Study Locations (20)
Michigan
- Henry Ford Cancer Institute-Downriver - Brownstown
- Henry Ford Health Center - Brownstown - Brownstown
- Henry Ford Health Center - Chesterfield - Chesterfield
- Henry Ford Macomb Hospital-Clinton Township - Clinton Township
- Henry Ford Medical Center-Fairlane - Dearborn
- Henry Ford Hospital - Detroit
- Henry Ford Medical Center - Detroit Northwest - Detroit
- Henry Ford Medical Center-Cottage - Grosse Pointe Farms
- Henry Ford Medical Center - Livonia - Livonia
- Henry Ford Medical Center-Columbus - Novi
Colorado
- Keefe Memorial Hospital - Cheyenne Wells
- Kaiser Permanente-Franklin - Denver
- Poudre Valley Hospital - Fort Collins
- Cancer Care and Hematology-Fort Collins - Fort Collins
- UCHealth Greeley Hospital - Greeley
- Kaiser Permanente-Rock Creek - Lafayette
- Kaiser Permanente-Lone Tree - Lone Tree
- Medical Center of the Rockies - Loveland
California
- Kaiser Permanente-Division of Research - Pleasanton
Hawaii
- Kaiser Permanente Moanalua Medical Center - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24,000 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2029-06-30 |
| Phase | NA |
What NCT06995898 shows while recruiting
NCT06995898 is an interventional study that assigns participants to a tested intervention. Its 24,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,004-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (2290% higher).
The record links to 10 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT06995898 names 20 study sites across 4 states, led by Michigan, Colorado, California.
Frequently Asked Questions
What is clinical trial NCT06995898 about?
NCT06995898 is a clinical study titled "The Vanguard Study: Testing a New Way to Screen for Cancer". The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand ho...
What is the current status of trial NCT06995898?
This trial is currently recruiting. It is a NA study. The enrollment target is 24,000 participants. The study started on 2025-06-16. Estimated completion is 2029-06-30.
What conditions does trial NCT06995898 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Ovarian Carcinoma.
What interventions are being tested in trial NCT06995898?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Electronic Health Record Review (OTHER), Device Usage (DEVICE), Multi-Cancer Detection Test (PROCEDURE).
Who is sponsoring clinical trial NCT06995898?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06995898 being conducted?
This trial has 20 study locations across California, Colorado, Hawaii, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06995898's enrollment target sits among peer trials
24,000 3rd of 176 higher than 174 of 176 other Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
RECRUITING · NA
-
Genetic Testing for the Prevention of Cancer in Indigenous American Communities (JUNIPER Trial)
RECRUITING · NA
-
Acupressure for the Reduction of Anxiety in Patients Receiving Cancer-Directed Therapy
RECRUITING · NA
-
Aromatherapy Essential Oils to Manage Anxiety and Nausea in Cancer Patients Receiving Infusion in the Ambulatory Setting
RECRUITING · NA
-
Community-Based Physical Activity Intervention for Underserved Cancer Survivors
RECRUITING · NA
-
Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04595201 · 25,000 participants
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
- NCT04994015 · 25,000 participants
Parkinson's Foundation PD GENEration Genetic Registry
- NCT06589310 · 25,000 participants
Falcon Real World Evidence Registry
- NCT06773897 · 25,000 participants
Rutgers University Study of the Genetics of Breast Cancer.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI